Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
about
Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in reviewSubverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancerHigh-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease modelUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies.Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma.Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan.Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral centerBortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterizationPhase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumorsClinical experience with temsirolimus in the treatment of advanced renal cell carcinomaAlleviating neurodegeneration in Drosophila models of PolyQ diseases.Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a ParadigmNCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyDrug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis.Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.Current treatment considerations in metastatic renal cell carcinoma.Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.Temsirolimus: a safety and efficacy review.Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings.Current status of DILD in molecular targeted therapies.Adverse events associated with mTOR inhibitors.Everolimus: side effect profile and management of toxicities in breast cancer.Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.Safety of mTOR inhibitors in adult solid organ transplantation.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.Interstitial lung disease induced by alectinib (CH5424802/RO5424802).PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.mTOR inhibitor-related pulmonary toxicity; incidence even higher.Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.
P2860
Q26774515-01026DE4-F7ED-4CEA-9D4E-B1E3EF5287ABQ26852704-A0CF1504-0701-44EE-9F6B-EF4FD62EE902Q27323092-E45D85F7-33C7-4706-A568-B3E65AE8D41CQ33408049-DA3A1C13-999D-4B4A-BA2A-47D33A7046B3Q33410008-CA6F6507-8CF2-4201-968E-31BBF1311A1BQ33410223-1B7293ED-6147-40C8-90AC-561DBF34E408Q34775380-BDE107A0-F4DC-4044-B983-8137F1F53DA2Q35051496-E6C151A1-C36F-4DFB-AEBC-2419716E0ED2Q35051964-E09E3BD5-6553-46A2-A131-BFFB0DAF2FD9Q35797388-26B3D6D1-9C3A-4768-BC8E-4701A651C0ACQ36003663-34B2A375-204C-4F1A-9EDC-D7C23F781915Q36064933-523016FC-C5B4-4EF7-A92B-46835B003DF4Q36318627-339EEB49-6757-44C7-B149-88CE62B1573AQ36494977-52CAACDD-2C0E-4775-B299-3148BA51344FQ37495852-49F01D3A-63BC-4A82-924C-BD83217A64A1Q37589551-80676BC4-0499-43DD-94B2-6FCF89B13D6AQ37621799-D4CE1D3B-2A68-4783-BA69-B7A100039539Q37992827-1087CF15-E1FD-41DE-86A5-2276F962A8ABQ38028411-F29E3FE3-9410-4701-B4FD-4F8909FA03E2Q38031941-577DFC5E-6E60-48DA-9F63-FF2057CB13B6Q38058679-68DE6BD6-40D4-48A9-9C71-A8EC11EF1F8AQ38059819-682D9A8C-CC90-4B6B-B294-CA9E7B4704EBQ38068519-D4A4A93C-9F08-4DCA-85C0-25235561679CQ38125944-D1645879-F99A-4F48-B064-A5E60CE64C2AQ38187149-12D96D36-FB6C-4991-A103-16E0CF52AB32Q38258712-52E4F94B-2D41-43A6-96C8-3C2F45B74A71Q38603164-8B9C2014-107E-4C9E-8273-5407FF0C104AQ38647604-C849FFDB-47F2-4BF4-86EC-C6B774458252Q38669190-85342353-8836-4C6A-AC46-C8030510C76EQ38962103-64E23030-67C9-4279-A0F4-877843793C1AQ39096266-16B2B29A-8D5A-42E8-A59D-FF57C53EB410Q41660655-D7BE3DA2-F373-43A3-AD2D-99826CB0522AQ46320590-3B4E8231-0C63-440A-BD9F-8DA10871E204Q46952013-8FE324C5-75BA-4376-B6A5-D0CC0E87491FQ50133191-96EB5E9B-E372-4F40-93D2-5DF262F45CC4Q53706060-11544286-A3E1-408E-B95C-6F6F72F83C9C
P2860
Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Drug-related pneumonitis in pa ...... oma treated with temsirolimus.
@ast
Drug-related pneumonitis in pa ...... oma treated with temsirolimus.
@en
Drug-related pneumonitis in pa ...... oma treated with temsirolimus.
@nl
type
label
Drug-related pneumonitis in pa ...... oma treated with temsirolimus.
@ast
Drug-related pneumonitis in pa ...... oma treated with temsirolimus.
@en
Drug-related pneumonitis in pa ...... oma treated with temsirolimus.
@nl
prefLabel
Drug-related pneumonitis in pa ...... oma treated with temsirolimus.
@ast
Drug-related pneumonitis in pa ...... oma treated with temsirolimus.
@en
Drug-related pneumonitis in pa ...... oma treated with temsirolimus.
@nl
P2093
P356
P1476
Drug-related pneumonitis in pa ...... oma treated with temsirolimus.
@en
P2093
Anna Berkenblit
Charles S White
Gary Hudes
Ignacio Duran
Janice P Dutcher
Jose Pablo Maroto
Maria Cincotta
Mark Shapiro
Mizue Krygowski
Theodore F Logan
P304
P356
10.1200/JCO.2010.29.2235
P407
P577
2011-03-28T00:00:00Z